Literature DB >> 25860200

[Serotonin syndrome and pain medication : What is relevant for practice?].

M Schenk1, S Wirz.   

Abstract

Serotonin syndrome is a dangerous and rare complication of a pharmacotherapy and can lead to death. Caused by unwanted interactions of serotonergic drugs, it is characterised by a neuroexcitatory triad of mental changes, neuromuscular hyperactivity and autonomic instability. Opioids with serotonergic effects include the phenylpiperidine series opioids fentanyl, methadone, meperidine and tramadol and the morphine analogues oxycodone and codeine. In combination with certain serotonergic drugs, e.g. antidepressants, they can provoke serotonin syndrome. In patients with such combinations, special attention should be paid to clinical signs of serotonergic hyperactivity. Higher risk combinations (e.g. monoamine oxidase inhibitors with tramadol) must be avoided. Treatment with serotonergic agents must be stopped in moderate or severe serotonin syndrome. Patients with a severe serotonin syndrome require symptomatic intensive care and specifically a pharmacological antagonism with cyproheptadine or chlorpromazine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25860200     DOI: 10.1007/s00482-015-1512-0

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  22 in total

Review 1.  The serotonin syndrome and its treatment.

Authors:  P K Gillman
Journal:  J Psychopharmacol       Date:  1999       Impact factor: 4.153

Review 2.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

Authors:  Magnus Ingelman-Sundberg
Journal:  Trends Pharmacol Sci       Date:  2004-04       Impact factor: 14.819

Review 3.  Case scenario: opioid association with serotonin syndrome: implications to the practitioners.

Authors:  Rahul Rastogi; Robert A Swarm; Trusharth A Patel
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

4.  Genes and the response to drugs.

Authors:  Yoseph Caraco
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

Review 5.  The serotonin syndrome.

Authors:  D Bijl
Journal:  Neth J Med       Date:  2004-10       Impact factor: 1.422

6.  The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.

Authors:  Randolph W Evans; Stewart J Tepper; Robert E Shapiro; Christina Sun-Edelstein; Gretchen E Tietjen
Journal:  Headache       Date:  2010-06       Impact factor: 5.887

7.  Tramadol increases extracellular levels of serotonin and noradrenaline as measured by in vivo microdialysis in the ventral hippocampus of freely-moving rats.

Authors:  P Bloms-Funke; E Dremencov; T I F H Cremers; T M Tzschentke
Journal:  Neurosci Lett       Date:  2010-12-31       Impact factor: 3.046

8.  Greater loss of 5-HT(2A) receptors in midlife than in late life.

Authors:  Yvette I Sheline; Mark A Mintun; Stephen M Moerlein; Abraham Z Snyder
Journal:  Am J Psychiatry       Date:  2002-03       Impact factor: 18.112

Review 9.  Serotonin syndrome and other serotonergic disorders.

Authors:  Rasih Atilla Ener; Sharon B Meglathery; William A Van Decker; Rollin M Gallagher
Journal:  Pain Med       Date:  2003-03       Impact factor: 3.750

10.  Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception.

Authors:  E E Codd; R P Shank; J J Schupsky; R B Raffa
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030

View more
  4 in total

Review 1.  [Piritramide : A critical review].

Authors:  M Hinrichs; A Weyland; C Bantel
Journal:  Schmerz       Date:  2017-08       Impact factor: 1.107

2.  [Side effects of pain therapy : Sufficient analgesia without unnecessary complications].

Authors:  F Greul; A Zimmer; W Meißner
Journal:  Urologe A       Date:  2017-04       Impact factor: 0.639

Review 3.  [Drug interactions in pain therapy].

Authors:  K M J Syhr; B G Oertel; G Geisslinger
Journal:  Schmerz       Date:  2015-12       Impact factor: 1.107

4.  Construction of a Virtual Opioid Bioprofile: A Data-Driven QSAR Modeling Study to Identify New Analgesic Opioids.

Authors:  Xuelian Jia; Heather L Ciallella; Daniel P Russo; Linlin Zhao; Morgan H James; Hao Zhu
Journal:  ACS Sustain Chem Eng       Date:  2021-03-04       Impact factor: 8.198

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.